{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:06:24Z","timestamp":1787313984594,"version":"build-2736575974"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Most older patients with esophageal cancer (EC) are unable to complete standard platinum-based concurrent chemoradiotherapy (CCRT) due to reduced organ reserve, comorbidities, and malnutrition. A new treatment option\u2014CCRT with S-1\u2014has been found to have high efficacy and fewer toxic effects for this population, yet long-term data supporting its use remain limited.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the long-term outcomes of CCRT with S-1 vs radiotherapy (RT) alone in older patients with EC.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This secondary analysis of a phase 3 randomized clinical trial conducted at 23 centers in China was not prespecified in the trial protocol. Patients aged 70 to 85 years with histologically confirmed EC were enrolled between June 1, 2016, and August 31, 2018. Data cutoff date was February 1, 2025, with an additional follow-up of 54 months beyond the primary analysis. Data were analyzed from February 1 to April 1, 2025.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n \n Patients were randomly assigned 1:1 to receive CCRT with S-1 consisting of 54 Gy in 30 fractions with S-1, 70 mg\/m\n 2<\/jats:sup>\n per day on days 1 to 14 and 29 to 42, or RT alone consisting of 60 Gy in 30 fractions, 2.0 Gy per day 5 days per week.\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was overall survival (OS). Secondary outcomes were progression-free survival (PFS), cause-specific mortality, cumulative incidence of death from EC or other reasons, and cumulative incidences of locoregional or distant metastasis during treatment or relapse after treatment.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 298 patients (median [IQR] age, 77 [74-79] years; 180 males [60.4%]) were enrolled. There were 151 patients (50.7%) clinically diagnosed with stage III to IV disease. With a median (IQR) follow-up of 87 (85-92) months, the median OS was 24.7 (95% CI, 21.2-37.6) months in the CCRT group and 15.1 (95% CI, 12.4-18.6) months in the RT group (hazard ratio [HR], 0.69; 95% CI, 0.53-0.90;\n P<\/jats:italic>\n \u2009=\u2009.005). The 5-year OS rates were 33.5% (95% CI, 26.7%-42.1%) and 24.4% (95% CI, 18.3%-32.4%) for the CCRT and RT groups, respectively; the 8-year OS rates were 26.2% and 16.1%, respectively. The median PFS was 18.7 (95% CI, 13.1-25.8) months in the CCRT group and 9.2 (95% CI, 7.9-12.7) months in the RT group (HR, 0.69; 95% CI, 0.54-0.90;\n P<\/jats:italic>\n \u2009=\u2009.005). Cause-specific analyses showed reduced EC-related mortality with CCRT (HR, 0.67; 95% CI, 0.50-0.89;\n P<\/jats:italic>\n \u2009=\u2009.005), with 8-year absolute risks of 58.5% vs 72.9%, respectively, and no excess noncancer-related mortality.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this secondary analysis of a randomized clinical trial, long-term results showed that CCRT with S-1 was associated with a sustained survival benefit compared with RT alone, without increased noncancer-related mortality. This finding supports CCRT with S-1 as the preferred regimen for patients aged 70 to 85 years with EC.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT02813967<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.3541","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:30:25Z","timestamp":1774625425000},"page":"e263541","source":"Crossref","is-referenced-by-count":1,"title":["Long-Term Outcomes of Concurrent Chemoradiotherapy With S-1 in Older Patients With Esophageal Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Yongling","family":"Ji","sequence":"first","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Science, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Fang","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Science, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanguang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Nantong Tumor Hospital, Nantong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, First Affiliated Hospital of University of Science and Technology of China, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Chongqing Sanxia Central Hospital, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiancheng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Thoracic Radiation, Fujian Provincial Cancer Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Jiangsu Cancer Hospital, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhong","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Huaian Second People's Hospital, Huaian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihua","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Taizhou Hospital of Zhejiang Province, Taizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First People's Hospital of Changzhou, Changzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Bao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dexi","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Lishui Municipal Central Hospital, Lishui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Degan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xinghua City People's Hospital, Xinghua, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiusheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoming","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Maoming People's Hospital, Maoming, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Hospital of Jiaxing, Jiaxing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zeng","sequence":"additional","affiliation":[{"name":"Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Liu","sequence":"additional","affiliation":[{"name":"The Tenth Affiliated Hospital of Southern Medical University, Dongguan People's Hospital, Dongguan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shangrao People's Hospital, Shangrao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Pu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Lianshui County People's Hospital, Lianshui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Chemoradiotherapy, Yinzhou People's Hospital, Ningbo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangyuan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Jinhua People\u2019s Hospital, Jinhua, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Wang","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Science, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peijing","family":"Li","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Science, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wang","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Science, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Xu","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Science, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zheng","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Science, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keying","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanwei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangzhou","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Nantong Tumor Hospital, Nantong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jizhong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Nantong Tumor Hospital, Nantong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Jiangsu Cancer Hospital, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Jiangsu Cancer Hospital, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Huaian Second People's Hospital, Huaian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First People's Hospital of Changzhou, Changzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xinghua City People's Hospital, Xinghua, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Bu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binbin","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Hospital of Jiaxing, Jiaxing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Xie","sequence":"additional","affiliation":[{"name":"Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Huang","sequence":"additional","affiliation":[{"name":"Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanda","family":"Zheng","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Science, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Sheng","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Science, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Lai","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Science, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Science, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cheng","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Science, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Hu","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Science, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Ji","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Science, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Kong","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Science, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofu","family":"Yu","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Science, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizhang","family":"Li","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Science, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runhua","family":"Li","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Science, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First People's Hospital of Foshan, Foshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"He","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First People's Hospital of Foshan, Foshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghui","family":"Du","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Science, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Chen","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, United Laboratory of Frontier Radiotherapy Technology of Sun Yat-sen University & Chinese Academy of Sciences Ion Medical Technology Co Ltd, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"issue":"3","key":"zoi260143r1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"zoi260143r2","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jamaoncol.2021.6987","article-title":"Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019.","volume":"8","author":"Kocarnik","year":"2022","journal-title":"JAMA Oncol"},{"issue":"24","key":"zoi260143r5","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1056\/NEJM199206113262403","article-title":"Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.","volume":"326","author":"Herskovic","year":"1992","journal-title":"N Engl J Med"},{"issue":"20","key":"zoi260143r6","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1200\/JCO.18.02122","article-title":"Comparing paclitaxel plus fluorouracil versus cisplatin plus fluorouracil in chemoradiotherapy for locally advanced esophageal squamous cell cancer: a randomized, multicenter, phase III clinical trial.","volume":"37","author":"Chen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"22","key":"zoi260143r7","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology.","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"zoi260143r8","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1080\/0284186X.2018.1450521","article-title":"Definitive chemoradiation or surgery in elderly patients with potentially curable esophageal cancer in the Netherlands: a nationwide population-based study on patterns of care and survival.","volume":"57","author":"Ko\u00ebter","year":"2018","journal-title":"Acta Oncol"},{"issue":"6","key":"zoi260143r9","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/COC.0b013e3180ca7c84","article-title":"A retrospective study of definitive chemoradiotherapy for elderly patients with esophageal cancer.","volume":"30","author":"Takeuchi","year":"2007","journal-title":"Am J Clin Oncol"},{"issue":"7","key":"zoi260143r10","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/j.1442-2050.2010.01062.x","article-title":"Esophageal cancer: definitive chemoradiotherapy for elderly patients.","volume":"23","author":"Wakui","year":"2010","journal-title":"Dis Esophagus"},{"issue":"10","key":"zoi260143r11","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/sj.bjc.6604749","article-title":"Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer.","volume":"99","author":"Tougeron","year":"2008","journal-title":"Br J Cancer"},{"issue":"3","key":"zoi260143r12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.21037\/jtd.2016.02.70","article-title":"A phase I dose escalation study of S-1 with concurrent radiotherapy in elderly patients with esophageal cancer.","volume":"8","author":"Ji","year":"2016","journal-title":"J Thorac Dis"},{"issue":"47","key":"zoi260143r13","doi-asserted-by":"publisher","first-page":"83022","DOI":"10.18632\/oncotarget.20938","article-title":"A phase II study of S-1 with concurrent radiotherapy in elderly patients with esophageal cancer.","volume":"8","author":"Ji","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"zoi260143r14","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1001\/jamaoncol.2021.2705","article-title":"Efficacy of concurrent chemoradiotherapy with S-1 vs radiotherapy alone for older patients with esophageal cancer: a multicenter randomized phase 3 clinical trial.","volume":"7","author":"Ji","year":"2021","journal-title":"JAMA Oncol"},{"issue":"5","key":"zoi260143r15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.12625","article-title":"Effectiveness of S-1-based chemoradiotherapy in patients 70 years and older with esophageal squamous cell carcinoma: a randomized clinical trial.","volume":"6","author":"Wang","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi260143r16","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1186\/s12877-024-04939-w","article-title":"Conditional survival and annual hazard of death in older patients with esophageal cancer receiving definitive chemoradiotherapy.","volume":"24","author":"Chang","year":"2024","journal-title":"BMC Geriatr"},{"issue":"1","key":"zoi260143r17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13014-024-02414-9","article-title":"Multicenter analysis on the value of standard (chemo)radiotherapy in elderly patients with locally advanced adenocarcinoma of the esophagus or gastroesophageal junction.","volume":"19","author":"Bostel","year":"2024","journal-title":"Radiat Oncol"},{"issue":"12","key":"zoi260143r18","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1002\/cam4.1250","article-title":"Treatment utilization and outcomes in elderly patients with locally advanced esophageal carcinoma: a review of the National Cancer Database.","volume":"6","author":"Vlacich","year":"2017","journal-title":"Cancer Med"},{"issue":"1","key":"zoi260143r19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13014-018-1044-8","article-title":"Clinical outcome of elderly patients (=?70 years) with esophageal cancer undergoing definitive or neoadjuvant radio(chemo)therapy: a retrospective single center analysis.","volume":"13","author":"Walter","year":"2018","journal-title":"Radiat Oncol"},{"key":"zoi260143r20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.839765","article-title":"Long-term results of a phase 2 study of definitive chemoradiation therapy using S-1 for esophageal squamous cell carcinoma patients who were elderly or with serious comorbidities.","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"zoi260143r21","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/ijc.34030","article-title":"Comparison of concurrent chemoradiotherapy with radiotherapy alone for locally advanced esophageal squamous cell cancer in elderly patients: a randomized, multicenter, phase II clinical trial.","volume":"151","author":"Liu","year":"2022","journal-title":"Int J Cancer"},{"issue":"17","key":"zoi260143r22","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1001\/jama.281.17.1623","article-title":"Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01).","volume":"281","author":"Cooper","year":"1999","journal-title":"JAMA"},{"issue":"6","key":"zoi260143r23","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.21037\/jtd.2019.06.24","article-title":"Age at diagnosis is a heterogeneous factor for non-small cell lung cancer patients.","volume":"11","author":"Chen","year":"2019","journal-title":"J Thorac Dis"},{"issue":"10","key":"zoi260143r24","doi-asserted-by":"publisher","first-page":"e663","DOI":"10.1016\/S2666-7568(21)00179-3","article-title":"Is cancer biology different in older patients?","volume":"2","author":"Van Herck","year":"2021","journal-title":"Lancet Healthy Longev"},{"issue":"21","key":"zoi260143r25","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1158\/1078-0432.CCR-18-1116","article-title":"Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations.","volume":"24","author":"Kugel","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"3","key":"zoi260143r26","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1001\/jamaoncol.2022.6901","article-title":"Association between age and survival trends in advanced non-small cell lung cancer after adoption of immunotherapy.","volume":"9","author":"Voruganti","year":"2023","journal-title":"JAMA Oncol"},{"issue":"12","key":"zoi260143r27","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1001\/jamaoncol.2019.2055","article-title":"Factors associated with age disparities among cancer clinical trial participants.","volume":"5","author":"Ludmir","year":"2019","journal-title":"JAMA Oncol"},{"issue":"13","key":"zoi260143r28","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer.","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"issue":"10302","key":"zoi260143r29","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"zoi260143r3","unstructured":"National Cancer Institute. SEER cancer stat facts: esophageal cancer. Accessed April 20, 2025. https:\/\/seer.cancer.gov\/statfacts\/html\/esoph.html"},{"key":"zoi260143r4","unstructured":"World Health Organization. Ageing and health, 2024. Accessed April 20, 2025. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/ageing-and-health"},{"key":"zoi260143r30","unstructured":"Study of durvalumab versus placebo in combination with definitive chemoradiation therapy in patients with ESCC (KUNLUN). ClinicalTrials.gov identifier: NCT04550260. Updated on January 29, 2026. Accessed February 13, 2026. https:\/\/clinicaltrials.gov\/study\/NCT04550260?term=NCT04550260&rank=1"},{"key":"zoi260143r31","unstructured":"Study of pembrolizumab (MK-3475) versus placebo in participants with esophageal carcinoma who are receiving chemotherapy and radiation therapy (MK-3475-975\/KEYNOTE-975). ClinicalTrials.gov identifier: NCT04210115. Updated November 15, 2024. Accessed February 13, 2026. https:\/\/clinicaltrials.gov\/study\/NCT04210115?term=NCT04210115&rank=1"},{"key":"zoi260143r32","unstructured":"A study to investigate tislelizumab (BGB-A317) versus placebo in combination with concurrent chemoradiotherapy in participants with localized esophageal squamous cell carcinoma. ClinicalTrials.gov identifier: NCT03957590. Updated May 2, 2025. Accessed February 13, 2026. https:\/\/clinicaltrials.gov\/study\/NCT03957590?term=NCT03957590&rank=1"},{"key":"zoi260143r33","unstructured":"Study of camrelizumab (SHR-1210) in combination with concurrent chemoradiotherapy in locally advanced esophageal cancer. ClinicalTrials.gov identifier: NCT04426955. Updated September 16, 2021. Accessed February 13, 2026. https:\/\/clinicaltrials.gov\/study\/NCT04426955?term=NCT04426955&rank=1"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2847026\/ji_2026_oi_260143_1774025004.02706.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:30:31Z","timestamp":1774625431000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2847026"}},"subtitle":["A Secondary Analysis of a Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.3541","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]}}}